Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 28 Oct, 15:53 UTC

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

science

Sources

• T2Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialBioPharma Dive / Healthcare Dive / MedTech Dive28 Oct, 15:53